RxDoctor Payments Data

Jeffrey Harvey

Optometrist · Kinston, NCNPI 1528012994

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 26 payments — averaging $38.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$359
  • AbbVie$173
  • Johnson & Johnson Vision Care, Inc.$169
  • Sun Pharmaceutical Industries Inc.$139
  • Bausch & Lomb Americas Inc.$94
  • Mallinckrodt Hospital Products Inc.$21
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$98898%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,007 in reported general payments places this provider in the 45th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$85,255
Medicare patients
504
Services billed
5,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost87$27,048
RestasisCyclosporine26$17,108
CombiganBrimonidine Tartrate/Timolol38$10,082
VyzultaLatanoprostene Bunod16$7,651
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol47$6,137
Latanoprost803$4,665
Tobramycin-DexamethasoneTobramycin/Dexamethasone55$2,733
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat226$2,707
Travoprost18$2,466
Fluorometholone29$1,770
Prednisolone Acetate19$728
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha25$276
Timolol Maleate23$244
Brimonidine Tartrate14$204
Dorzolamide Hcl17$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$173$54,238151 claims
Bausch & Lomb Americas Inc.Vyzulta$94$7,65116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Kinston

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →